Flavocillin: a potent TrxR and OATP inhibitor

Flavocillin, a newly discovered beta-lactam antibiotic, shows promise in its ability to be a TrxR and OATP inhibitor. Through our docking experiments, we identified key residues in the docking process, that proves the idea that this molecule can increase the susceptibility of various bacteria to beta-lactams since it has been proven that the combination of TrxR inhibitors, along with beta-lactams, can minimize the creation of MRSA. Also, Flavocillin shows an affinity for the metallo beta-lactamase, omitting the use of clavulanic acid. Possibly, the combination of Flavocillin with other beta-lactams, as a therapeutic approach, could minimize the chances of creating antibiotic-resistant strains.